Chongqing Zhifei Biological Products Co., Ltd. Class ASZSE: 300122

Chongqing Zhifei Biological Products Co: First annual net loss driven by industry downturn and asset impairment, but liquidity and R&D held firm

· Issued by Chongqing Zhifei Biological Products Co., Ltd. Class A

2025 saw a historic net loss due to industry headwinds, asset impairment, and weak sales, but liquidity and debt were stabilized, R&D remained strong, and strategic partnerships were restructured to reduce risk. The company is focused on accelerating product launches and international growth.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

Company analysis

Earlier from Chongqing Zhifei Biological Products Co., Ltd. Class A

All Chongqing Zhifei Biological Products Co., Ltd. Class A news releases